参附注射液对全身炎症反应综合征的临床干预作用及机制研究

目的:探讨参附注射液对全身炎症反应综合征(SIRS)的临床干预作用及对核因子-κB(NF-κB)活性的影响,以初步阐明其机制。方法:选取我院满足SIRS纳入标准的患者18名,随机分为3组:空白对照组、生理盐水治疗组和参附注射液(SF)治疗组,每组6例。经相应治疗后,采用酶联免疫法(ELISA)分别检测各组患者不同时间点血液中单个核细胞NF-κB、血清肿瘤坏死因子-α(TNF-α)、白介素-6(IL-6)水平变化。结果:参附注射液治疗组患者血NF-κB、TNF-α、IL-6水平第1天达最高水平,随后逐渐下降,与空白对照组及生理盐水组比较具有显性差异(P0.05)。结论:参附注射液可能通过减少NF-κB的激活,降低TNF-α和IL-6的释放,进而减轻肺脏和肝脏的病理损伤,对全身炎症反应综合征起保护作用。

The Study of Clinic Intervention Effect of Shenfu Injection on Systemic Inflammatory Response Syndrome and its Mechanism

Objective To study the clinic intervention effect of Shenfu injection（SF） on systemic inflammatory response syndrome （SIRS） and the activity of nuclear factor-κB （NF-κB）, and initially elucidate its mechanism. Methods The 18 patients in our hospital met the inclusion criteria of SIRS were randomly divided into three groups： the control group, the normal sodium（NS） group and the SF treatment group, with 6 cases in each group. After treating respectively, the levels of blood mononuclear cell nuclear factor-κB（NF-κB）, serum tumor necrosis factor -α （TNF-α）, interleukin -6 （IL-6） at different time point were all detected by using euzymelinked immunosorbent assay（ELISA） technique. Results The blood levels of NF-κB, TNF-α, IL-6 in SF treatment group were increased to the highest level at the first day, then they were fallen-off gradually. Compared with the control group and the normal sodium（NS） group, the differences were statistically significant （P〈 0.05）. Conclusion SF injection can reduce the activation of NF-κB, decrease the release of TNF-α and IL-6, and then alleviate the pathological damage of lung and liver, so play a role of protection for patients with SIRS. SF injection has a certain therapeutic effect on SIRS.